Oruka Therapeutics Inc. Common Stock (ORKA)

FairStock Score: 29/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I start with earning power, and Oruka Therapeutics has none. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $41.2 million. That followed a $31.8 million loss in fiscal Q1 2026 and a $30.3 million loss in fiscal Q3 2025. For FY2025, ended 2025-12-31, the net loss was $105.4 million. No revenue appears in any filed period. The company is clinical-stage, with ORKA-001 and ORKA-002 in phase 2/2a trials for psoriasis and related inflammatory conditions. That is a promising field, but promise is not a moat. There are no approved products, no pricing power, no recurring revenue, and no demonstrated competitive advantage—only the possibility of one if trials succeed. On financial health, FairStock shows D/E of 0.00 and an Altman Z-score of 112.41, suggesting low leverage. But trailing free cash flow is -$101.2 million and FCF yield is -2.0%; cash is being consumed. The Piotroski F-score is 2/9, a weak reading. Valuation also demands caution. At the 2026-10-13 close of $78.19, the market cap is $5.2 billion. FairStock calculates P/B at 4.30 and P/E at -38.33; a negative P/E simply confirms losses. Paying $5.2 billion for a pre-revenue company with widening losses requires assuming clinical and commercial success. Graham would call this speculation, not an investment with a margin of safety. Buffett would ask for durable economics; I see none yet. The stock may move on trial data, but it is not a business I can value on earnings.

In plain English: Oruka Therapeutics is a clinical-stage biotech company developing antibody drugs for psoriasis and other inflammatory diseases. It has no product revenue and has been losing money, with recent losses growing. The stock closed at $78.19 on 2026-10-13 with a $5.2 billion market value, which looks expensive for a company with no sales or profits yet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2023 10-K (period ended 2023-12-31) · FY2022 10-K (period ended 2022-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer